Welcome to our dedicated page for KNEAT COM news (Ticker: KSIOF), a resource for investors and traders seeking the latest updates and insights on KNEAT COM stock.
kneat.com, inc. develops digital validation and quality process automation software for highly regulated industries. Its Kneat Gx platform is used to manage validation disciplines end to end, with compliance features tied to GxP environments, data integrity, 21 CFR Part 11/Annex 11 requirements, and ISO 9001 and ISO 27001 certification.
Company news commonly covers customer agreements with life sciences, CDMO, pharmaceutical packaging, and biopharma manufacturing organizations; financial results and shareholder communications; platform capabilities including optional AI tools; and the company’s State of Validation research on digitization, validation workload, and compliance practices.
Kneat (TSX: KSI; OTCQX: KSIOF) will release first-quarter 2026 financial results for the quarter ended March 31, 2026, after TSX market close on May 13, 2026. A webcast conference call with CEO Eddie Ryan and CFO Dave O’Reilly will follow on May 14, 2026 at 09:00 ET (14:00 GMT).
According to the company, the webcast registration and the Q1 2026 results will be available in the Financial Information section of the Kneat Investors page at kneat.com/investors.
Kneat (OTCQX: KSIOF) released its 2025 shareholder letter highlighting resilient growth amid industry headwinds. The company reported software revenue +33% in 2025, $74M+ Annual Recurring Revenue and a Net Revenue Retention of 115%.
Kneat cited record new customers, 100% retention among core strategic customers, AI features for GxP environments, a 98/100 G2 satisfaction score, and an NPS above 70. Management expects improving operating efficiency and a path to cash-flow breakeven in 2026.
Kneat (OTCQX: KSIOF) reported record fourth-quarter and full-year 2025 results, with total revenue of $17.0M Q4 (+24% YoY) and $63.3M for 2025 (+29% YoY). ARR reached $74.1M at year-end (+24% YoY). Gross margin improved to 76–78%, Adjusted EBITDA was $9.5M for 2025, and net loss narrowed to $2.3M.
The company highlighted record new customer wins, strategic partnerships (Capgemini), AI product enhancements, leadership changes, and a 2026 target of cash-flow breakeven while anticipating typical second-half seasonality.
Kneat (TSX: KSI / OTCQX: KSIOF) announced a signed Master Services Agreement with a U.S.-headquartered global pharmaceutical packaging and drug-delivery manufacturer on Feb 19, 2026. The customer operates >45 manufacturing sites, including >12 GMP-regulated facilities, and employs over 13,000 people worldwide.
Under the agreement the customer will initially deploy Kneat Gx for CQV at a lead site, with planned expansion to all GMP sites, citing Kneat’s data integrity and audit-ready capabilities as decisive.
Kneat (OTCQX: KSIOF, TSX: KSI) said it will release fourth-quarter and full-year 2025 financial results after TSX close on February 25, 2026. A webcasted conference call and Q&A with CEO Eddie Ryan and CFO Dave O’Reilly is scheduled for February 26, 2026 at 09:00 ET (14:00 GMT).
Financial results will be posted in the Financial Information section of Kneat’s investors page at https://kneat.com/investors/.
Kneat (OTCQX: KSIOF) on January 6, 2026 announced a Master Services Agreement with a Europe‑headquartered biopharma research and manufacturing technology provider that employs 13,000+ people and operates in more than 60 locations. The customer will begin deploying Kneat’s digital validation platform for equipment validation at several manufacturing sites worldwide.
Kneat said the vendor selection followed a comprehensive evaluation citing measurable ROI and prior life‑sciences deployments. Management expects the customer to expand use enterprise‑wide over time, and the agreement is presented as reinforcing Kneat’s market position and supporting continued revenue growth.
Kneat (OTCQX: KSIOF) signed a three-year Master Services Agreement with one of the world’s largest specialty chemicals makers on Dec 17, 2025, adding momentum to a record year for new customer additions.
The customer has a Europe HQ, a footprint in >100 countries, manufacturing in >24 countries, and >30,000 employees. Kneat will deploy Kneat Gx for Computer System Validation (CSV), Equipment Validation, and electronic logbooks. Kneat cites ease of use, no-code configurability, data integrity, and validation expertise as competitive strengths driving high win rates in 2025.
Kneat (OTCQX: KSIOF) reported Q3 2025 total revenue $16.1M, up 26% year over year, driven by SaaS revenue $15.2M (+33% YoY). Gross profit was $12.2M and gross margin held near prior levels at 76%. ARR reached $68.6M, up 37% YoY. Q3 EBITDA was $3.8M and Adjusted EBITDA was $2.5M; Q3 net loss was $0.5M. Year-to-date revenue rose 31% to $46.3M and YTD EBITDA improved to $13.5M. Management highlighted new three-year MSAs, G2 category rankings, and AI product advancements while hosting a webcast on Nov 13, 2025.
Kneat (OTCQC: KSIOF) has secured a significant Master Services Agreement with a major U.S.-based multinational manufacturer of advanced devices and components. The client company, which employs over 30,000 people across 30+ countries, will implement the Kneat Gx platform for two primary purposes:
The platform will be used for Computer Systems Validation across enterprise applications and for Commissioning, Qualification and Validation at 18 manufacturing sites within its medical and healthcare division. This strategic partnership demonstrates Kneat's expanding presence in the life sciences sector beyond pharmaceuticals.
Kneat (OTCQX: KSIOF), a leader in validation and quality process digitization, has achieved top rankings in G2's Fall 2025 Pharma and Biotech Software category reports. The company secured leadership positions in three categories with an impressive G2 Satisfaction Score of 98/100, surpassing the second-ranked company by 20 points.
The company earned leadership recognition in the Grid® Report, Relationship Index, and Mid-Market Grid® Report for Pharma and Biotech. Additionally, Kneat ranked second in the G2 Pharma and Biotech Usability Index, demonstrating strong performance in administration, ease of use, and requirements fulfillment.